Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PNU 166196

Known as: PNU-166196, PNU166196 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Brostallicin (PNU-166196), a-bromo-acrylamido tetra-pyrrole derivative, showed high cytotoxic potency and myelotoxicity… Expand
2004
2004
The mechanism of action of many antitumor agents involves DNA damage, either by direct binding of the drug to DNA or to DNA… Expand
2003
2003
Defects in DNA mismatch repair (MMR) are associated with a predisposition to tumorigenesis and with drug resistance owing to high… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2003
2003
PURPOSE Brostallicin (PNU-166196) is a cytotoxic agent that binds to the minor groove of DNA with significant antitumor activity… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Review
2003
Review
2003
DNA minor groove binders (MGB) represent a class of anticancer agents whose DNA sequence specificity was hypothesized to lead to… Expand
2003
2003
PURPOSE Brostallicin (PNU-166196) is a alpha-bromoacrylic DNA minor groove binder, currently in clinical evaluation. This drug… Expand
2003
2003
Purpose: Brostallicin (PNU-166196) is a cytotoxic agent that binds to the minor groove of DNA with significant antitumor activity… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2002
Highly Cited
2002
Brostallicin (PNU-166196) is a synthetic alpha-bromoacrylic, second-generation DNA minor groove binder structurally related to… Expand
  • figure 1
  • table 1
  • table 2
  • table 4
  • figure 2
Review
2001
Review
2001
The relatively low therapeutic index of the clinically used alkylating agents is probably related to the fact that these… Expand
2001
2001
DNA minor groove binders represent a class of cytotoxic antitumor agents whose DNA sequence specificity may lead to a high… Expand